Subscribe To

Price Alert Latest News Economic Calendar News

BIVI / BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in patients with mild to moderate Alzheimer's Disease (AD), and it expects to announce topline data from the trial in November or December. BioVie's shares moved higher on the news, adding 4.6% to US$3.40 in pre-market trading. Read More

Demo Live Account See Partner Details

Content Topics

Biovie

Announce

Topline

Data

From

Phase

Alzheimer

Disease

Alzheimer s

Year end

Stock

BIVI

Posted: Sep 26 2023, 09:11

Author Name: Proactive Investors

BIVI News

By Proactive Investors
October 25, 2023

BioVie says blinded data points to hopeful Alzheimer's treatment potential

BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its

By Zacks Investment Research
October 19, 2023

New Strong Buy Stocks for October 19th

INTA, NU, ENLV, VCEL and BIVI have been added to the Zacks Rank #1 (Strong Buy) List on October 19, 2023.

By Proactive Investors
September 26, 2023

BioVie complements its Alzheimer's clinical research program with social impact initiatives

What sets BioVie Inc (NASDAQ:BIVI) apart from many of its biotechnology peers is the fact it has appointed a Chief Social Impact Officer whose role is

By Proactive Investors
September 26, 2023

BioVie to announce topline data from Phase 3 Alzheimer's Disease trial by year-end

BioVie Inc (NASDAQ:BIVI) said the last patient has completed their final visit at week 30 in their Phase 3 study of investigational therapy NE3107 in

By Proactive Investors
September 11, 2023

BioVie presents Alzheimer's study data on patient's baseline characteristics

BioVie Inc (NASDAQ:BIVI) has unveiled early data from its Phase 3 study of its investigational drug NE3107 in patients with mild to moderate Alzheimer

By Benzinga
September 6, 2023

Top 5 Health Care Stocks That May Explode In Q3 - BioVie (NASDAQ:BIVI), Galera Therapeutics (NASDAQ:GRTX)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

By Zacks Investment Research
August 30, 2023

Down -26.93% in 4 Weeks, Here's Why BioVie Inc. (BIVI) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical m

By Zacks Investment Research
August 28, 2023

Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. (BIVI)

BioVie Inc. (BIVI) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with str

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.